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Conductance Regulator–Mediated Regulation of Separate Channels
John E. Mickle,1 Michał I. Milewski,1 Milan Macek, Jr.,2 and Garry R. Cutting1
1Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore; and 2Institute of Biology and Medical Genetics,
Department of Molecular Genetics, Cystic Fibrosis Center, University Hospital Motol and Second School of Medicine of Charles University,
Prague
The protein defective in cystic fibrosis (CF), the CF transmembrane-conductance regulator (CFTR), functions as
an epithelial chloride channel and as a regulator of separate ion channels. Although the consequences that disease-
causing mutations have on the chloride-channel function have been studied extensively, little is known about the
effects that mutations have on the regulatory function. To address this issue, we transiently expressed CFTR-bearing
mutations associated with CF or its milder phenotype, congenital bilateral absence of the vas deferens, and deter-
mined whether mutant CFTR could regulate outwardly rectifying chloride channels (ORCCs). CFTR bearing a
CF-associated mutation in the first nucleotide-binding domain (NBD1), DF508, functioned as a chloride channel
but did not regulate ORCCs. However, CFTR bearing disease-associated mutations in other domains retained both
functions, regardless of the associated phenotype. Thus, a relationship between loss of CFTR regulatory function
and disease severity is evident for NBD1, a region of CFTR that appears important for regulation of separate
channels.
Introduction
The autosomal recessive disorder cystic fibrosis (CF
[MIM 219700]) manifests as chronic obstructive pul-
monary disease, exocrine pancreatic deficiency, high con-
tent of sodium and chloride in sweat, and male infertility.
These features are believed to be caused by abnormal
electrolyte transport across epithelia, which leads to al-
tered mucous viscosity and recurrent episodes of ob-
struction, inflammation, and progressive destruction of
affected organs (Welsh et al. 1995). Initial electrophy-
siological studies of CF epithelial cells described the ab-
normal regulation of outwardly rectifying chloride chan-
nels (ORCCs); consequently, this abnormal regulation
was implicated as the molecular defect underlying CF
(Frizzell et al. 1986; Welsh and Liedtke 1986; Li et al.
1988; Hwang et al. 1989). Positional cloning of the gene
responsible for CF provided a major breakthrough in
the understanding of the molecular basis for this disease:
CF is caused by mutations in the CF transmembrane-
conductance regulator (CFTR [MIM 602421]) (Kerem
et al. 1989; Riordan et al. 1989).
Received April 12, 1999; accepted for publication February 16,
2000; electronically published April 4, 2000.
Address for correspondence and reprints: Dr. Garry R. Cutting, In-
stitute for Genetic Medicine, CMSC 9-120, Johns Hopkins University
School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287.
E-mail: gcutting@welchlink.welch.jhu.edu
q 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6605-0003$02.00
CFTR is an integral membrane protein composed of
two repeated units, each with a transmembrane domain
(TMD) and cytoplasmic nucleotide-binding fold (NBF),
separated by a regulatory (R) domain (Riordan et al.
1989). This protein functions as a cAMP-activated Cl2
channel, which meets the expectation that a chloride-
transport defect is the underlying cause of CF (Drumm
et al. 1990; Anderson et al. 1991; Bear et al. 1992).
However, the Cl2 conduction properties of CFTR are
different from properties of the ORCCs previously char-
acterized in CF cells (Ward et al. 1991; Egan et al. 1992).
An association between CFTR and ORCCs has been
demonstrated by heterologous expression of CFTR in
an epithelial cell line devoid of endogenous CFTR func-
tion. ORCC activity has been recovered in the comple-
mented cells, and its regulation has been found to be
similar to that in wild-type epithelial cells (Egan et al.
1992). This result implies either that CFTR forms more
than one type of channel or that the ORCCs are a sep-
arate entity regulated by CFTR.
Three lines of evidence indicate that ORCCs are mo-
lecularly distinct from CFTR. First, functional mea-
surements of ORCC density in plasma membranes do
not correlate with the level of CFTR mRNA expression
in several different epithelia cell lines (Ward et al. 1991).
Second, ORCCs are present in nasal epithelial cells from
mice that do not express CFTR (CF mice) but cannot
be activated by cAMP-dependent protein kinase A (PKA
[Gabriel et al. 1993]). Finally, reconstitution of four
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proteins coprecipitated from bovine tracheal epithelia
forms channels in lipid bilayers with physiological char-
acteristics similar to those of the ORCCs and of CFTR.
Immunodepletion of CFTR by an anti-CFTR antibody
causes a loss of CFTR channels, and, although the
ORCCs remain, they cannot be activated by PKA (Jovov
et al. 1995). Thus, CFTR is a positive regulator of
ORCCs, and activation of ORCCs contributes to the
whole-cell chloride conductance in airway epithelial
cells (Schwiebert et al. 1994).
CFTR is also a regulator of epithelial sodium chan-
nels. In patients with CF, increased absorption of so-
dium by respiratory epithelia compounds the difficulty
in the hydrating of mucus secretions (Cotton et al.
1987). This electrophysiological abnormality has been
attributed to CFTR dysfunction: the nasal epithelial
cells from CF mice demonstrate Na1 hyperabsorption,
and heterologous expression of CFTR in primary CF
airway cells normalizes Na1 absorption (Grubb et al.
1994; Johnson et al. 1995). Functional cloning of the
three subunits that form the amiloride-sensitive epithe-
lial sodium channel (ENaC) enabled coexpression stud-
ies confirming the interaction between CFTR and this
separate channel (Stutts et al. 1995). In respiratory ep-
ithelia, activated CFTR exerts a regulatory effect on
ENaC, thereby reducing sodium absorption (Stutts et
al. 1995; Mall et al. 1998). Likewise, sodium absorption
via ENaC in sweat ducts requires functional CFTR
(Reddy et al. 1999). Therefore, in addition to the con-
ventional role of CFTR as a cAMP-activated chloride
channel, the examples of ORCC and ENaC clearly il-
lustrate that it is also a regulator of separate channels.
The effect that disease-associated CFTR mutations
have on the activity of ORCCs has been studied as a
proxy for the regulatory function of CFTR. Specifically,
two missense mutations in NBF1 have been evaluated:
A455E, which is associated with mild lung disease, and
G551D, which is associated with a more severe pul-
monary phenotype (Hamosh et al. 1992; Gan et al.
1995). CFTR bearing A455E retains both CFTR Cl2
channel activity and the ability to regulate ORCCs (Ful-
mer et al. 1995). In contrast, G551D-CFTR has some
Cl2 channel activity but does not regulate ORCCs (Ful-
mer et al. 1995). It has been demonstrated that G551D-
CFTR does not regulate the activity of ENaC (Ismailov
et al. 1996). These results suggest that loss of the reg-
ulatory activity may coincide with the severity of lung
disease. This hypothesis could explain the phenotypic
variation between CF and congenital bilateral absence
of the vas deferens (CBAVD [MIM 277180]). Even
though CBAVD is caused primarily by mutations in
CFTR, it is classified as a clinically distinct autosomal
recessive disorder of male infertility in which lung dis-
ease is uncommon. Thus, we have studied the biosyn-
thesis and function of CF- and CBAVD-associated mu-
tations. Although the common CF mutation DF508
causes a loss of CFTR regulatory function, mutations
in other regions permit CFTR regulation of ORCCs
independent of the associated phenotype.
Methods
Mutation Analysis of Patients with CBAVD
Genomic DNA was isolated by standard phenol and
chloroform extraction of proteinase K–digested leuko-
cytes. DNA was assayed for 16 common CFTR muta-
tions (R117H, 62111GrT, R334W, R349P, A455E,
DI507, DF508, 1717-1GrA, G542X, S549N, G551D,
R553X, R560T, 3849110 Kb CrT, W1282X, and
N1303K), by reverse dot-blot hybridization (Mickle et
al. 1998). In addition, 25 exons were screened by de-
naturing gradient gel electrophoresis, for mobility shifts,
and, if necessary, dideoxy DNA sequencing was per-
formed (Mickle et al. 1998). Exons 9 and 23 were se-
quenced directly.
Expression Analysis
The mutations DF508, R1070W, D1270N, and
G1349D were created in the vector pBQ4.7 containing
CFTR cDNA (pBQ4.7 is a gift from J. Rommens and
L. C. Tsui), by single-stranded mutagenesis (Youssoufian
et al. 1995), and then were shuttled into pRSV-CFTR,
a Rous sarcoma virus (RSV)-driven expression plasmid,
by use of Kpn2I and HpaI (for DF508) or NcoI and SalI
(for R1070W, D1270N, and G1349D) restriction sites
common to both plasmids (Fulmer et al. 1995). The
mutations R1070P and R1070Q were created directly
in pRSV-CFTR, by use of a transformer site–directed
mutagenesis kit (Clontech). Immunoprecipitation ex-
periments were performed, by use of the CFTR C-ter-
minus–specific monoclonal antibody (Genzyme), on lys-
ates of transiently transfected human embryonic kidney
(HEK) 293 cells, detailed elsewhere (Mickle et al. 1998).
Patch-Clamp Analysis
Whole-cell patch-clamp recordings were performed on
human airway (IB3-1) cells transiently transfected with
either pRSV-CFTR or pRSV-CFTR/mutant, as described
elsewhere (Mickle et al. 1998). IB3-1 bronchial epithelial
cells were derived from a patient with CF (genotype
DF508/W1282X); these cells lack functional CFTR
(Zeitlin et al. 1991). To facilitate detection of transfected
cells, IB3-1s were cotransfected with pTR-UF5 (Zolo-
tukhin et al. 1996), a green-fluorescent protein (GFP)
reporter plasmid, at a 10:1 ratio (pRSV-CFTR:pTR-
UF5). CFTR function was not altered by GFP coex-
pression (Mickle et al. 1998). Symmetrical Tris-HCl so-
lutions were used in the bath (145 mM Tris-HCl, pH
7.4, 1 mM CaCl2, 5 mM N-2-hydroxyethylpiperazine-
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N′-2-ethane-sulfonic acid [HEPES], 60 mM sucrose, and
1 mM MgCl2) and in the pipette (145 mM Tris-Cl, pH
7.4, 5 mM HEPES, 5 mM Mg21-ATP, 100 nM CaCl2,
and 2.5 mM ethylene glycol-bis[b-aminoethyl ether]-
N,N,N′,N′-tetra-acetic acid) solutions (Schwiebert et
al. 1994; Mickle et al. 1998). The holding potential was
set at 260 mV. A voltage-clamp protocol was followed,
stepping from 2100 mV to 1100 mV, at 20-mV incre-
ments, for a duration of 250 ms. Cells were pretreated
with CPT-cAMP (8-[4-chlorophenylthio]; 200 mM) and
forskolin (5 mM) for 5 min before the Cl2 channel block-
ers DIDS (4,4′-diisothiocyanato-stilbene-2,2′-disulfonic
acid; 500 mM) and glibenclamide (50 mM) were added
to the bath solution. Data points from steady-state levels
were taken to generate current-voltage (I-V) plots. Plots
were fitted by Origin 4.0 (Microcal). Unpaired and
paired Student’s t tests were used to assess statistical
significance of Cl2 currents between transfected and
nontransfected cells and between positive and negative
voltages, respectively; was considered to be signi-P ! .05
ficant.
Results
Selection of CF- and CBAVD-Associated Mutations
To study the relationship between lung disease and
CFTR function, we selected mutations that had been
reported in at least two unrelated individuals with either
CBAVD or CF. The clinical features and sweat tests are
summarized, according to mutation, in table 1. Muta-
tions at codon 1070 of TMD2 were selected, since two
mutations (R1070P and R1070Q) have been associated
with CF, whereas a third (R1070W) has been observed
in men with CBAVD (table 1). The R1070W mutation
was first reported by us to the Cystic Fibrosis Genetic
Analysis Consortium. The index case was a 3-mo-old
boy who, during surgery for a right inguinal hernia and
hydrocele, was discovered to have bilateral absence of
the vas deferens. Sweat Cl2 tests were normal at age 3
mo (14 mmol/liter and 16 mmol/liter) and at 9 mo (17
mmol/liter and 15 mmol/liter). At age 6 years, the patient
was pancreatic sufficient and was growing normally,
with no pulmonary problems. CFTR-mutation screening
revealed that the proband was compound heterozygous
for the common mutation DF508 and a CrT transition
at nucleotide 3340. The latter mutation is predicted to
change the amino acid at residue 1070 from arginine to
tryptophan and is designated “R1070W.” Also selected
for study were two mutations in NBF2—D1270N and
G1349D, which are associated with different pulmonary
phenotypes (table 1). The mutation D1270N has been
identified in at least nine men with CBAVD. For com-
parison purposes, we selected the CF-associated muta-
tion G1349D, since it occurs in the same functional do-
main as does D1270N.
Biosynthesis of CFTR Missense Mutants
A number of CF mutations have been shown to affect
the maturation of CFTR (Cheng et al. 1990). To deter-
mine whether the selected missense mutations affect
CFTR biosynthesis, HEK 293 cells were transiently
transfected with plasmid containing mutant CFTR
cDNA, and then each mutant was immunoprecipitated
by use of a monoclonal antibody specific for the carboxy
terminus of CFTR. CFTR was detected by PKA-medi-
ated 32P radiolabeling followed by SDS-PAGE and au-
toradiography. Molecular mass was determined by com-
parison with commercially available molecular markers
(RPN800; Amersham). Endogenous CFTR could not be
detected in untransfected or mock (pTR-UF5)-trans-
fected HEK 293 cells.
Wild-type CFTR migrated as a single band, at a mo-
lecular mass of ∼175 kD (fig. 1; Cheng et al. 1990;
Gregory et al. 1990). The 175-kD protein is the mature
form of CFTR and is designated as “band C” in figure
1. The NBF1 mutant DF508-CFTR migrated as two
bands, at ∼145 kD (fig. 1, band B) and ∼130 kD (fig.
1, band A). Band B is partially glycosylated protein;
whether band A is unglycosylated protein or some other
form is unclear (Cheng et al. 1990; Gregory et al. 1991).
Despite several attempts, we were unable to identify the
fully glycosylated, mature form of CFTR (i.e., band C)
for DF508-CFTR.
All three missense mutations at arginine 1070 affected
CFTR processing (fig. 1). R1070P(CF), like DF508, mi-
grated as bands B and A, but the fully glycosylated form
of CFTR (band C) was not observed. The R1070Q(CF)
and R1070W(CBAVD) mutants consistently migrated as
two bands; a minor fraction was partially glycosylated
(band B), whereas the majority was mature CFTR (band
C). Thus, mutations R1070Q and R1070W altered but
did not prohibit complex glycosylation. The NBF2 mu-
tants D1270N(CBAVD) and G1349D(CF) migrated like
wild-type CFTR (band C), leading to the conclusion that
neither mutation affects CFTR glycosylation (fig. 1).
Cl2 Channel and Regulatory Functions of CFTR
Missense Mutants
To assay each CFTR function, plasmids containing
wild-type CFTR, the DF508 mutant, and the missense
mutants in TMD2 and NBF2 were transiently expressed
in CF airway epithelial cells (IB3-1). This human cell
line was chosen because IB3-1 cells express ORCCs but
no functional CFTR (Egan et al. 1992). Whole-cell
patch-clamp recordings were performed under condi-
tions in which Cl2 was the predominant permeating an-
ion in pipette (intracellular) and bath (extracellular) so-
Table 1


















R1070W (7)d 5 0 2 5 0 2e 6 ( )50.2 5 13.4 1 6 1 CBAVD
R1070P (2)f 0 1 1 0 1 1 1 (Positive) 1 0 2 CF
R1070Q (14)g 0 7 7 0 7 7 7 (Positive) 7 2 12 CF
D1270N (9)h 4 0 5 4 0 5 3 ( )77.5 5 16.7 6 3 6 CBAVD
G1349D (3)i 0 0 3 0 0 3 ) 3 1 2 CF
a No history of chronic lung disease.
b Concentrations 160 mmol/liter are diagnostic of CF (i.e., positive).
c Decreased reproductive fitness. Although CBAVD occurs in men, the potential for assisted reproductive interventions precludes a designation of “infertile.”
d Data are from Casals et al. (1995), Chillo´n et al. (1995), Ferec et al. (1995), Jezequel et al. (1995), Le Lannou et al. (1995), Gervais et al. (1996), de la Taille et al.
(1998), and the present study.
e In one case, a newborn tested positive for immunoreactive trypsinogen.
f Data are from Shrimpton et al. (1997) and T. Doerk (personal communication).
g Data are from Audre´zet et al. (1993), Mercier et al. (1993, 1994), Osborne et al. (1993), Savov et al. (1994), Bienvenu et al. (1997), and Estivill et al. (1997).
h Data are from Anguiano et al. (1992), Claustres et al. (1993), Verlingue et al. (1993), Casals et al. (1995), Chillo´n et al. (1995), Mercier et al. (1995), Estivill et al.
(1997), Bombieri et al. (1998), and Fanen et al. (1999).
i Data are from Beaudet et al. (1991), Gregory et al. (1991), Anderson and Welsh (1992), Welsh and Smith (1993), Chillo´n et al. (1995), and Estivill et al. (1997).
The initial mutation report (Beaudet et al. 1991) indentified G1349D on two CF chromosomes, and, on the basis of these cases, G1349D has been described as a CF-
associated mutation (Gregory et al. 1991; Anderson and Welsh 1992), with specific reference to PI (Welsh and Smith 1993).
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Figure 1 Immunoprecipitation of TMD2 and NBF2 mutants transiently expressed in HEK 293 cells. The left panel is a cartoon of CFTR
and the relative location of mutations studied in this report; domains of CFTR are described in the text. The middle and right panels are
autoradiographs of wild-type and mutant CFTR proteins that were expressed in HEK 293 cells, immunoprecipitated with a monoclonal antibody
directed against the C-terminus, radiolabeled with 32P by use of PKA, and electrophoretically separated by SDS-PAGE. Wild-type CFTR was
fully processed (bands C). The DF508-CFTR is a processing mutant that migrated as two bands (bands B and bands A). The TMD2 mutants
affected processing to differing degrees: R1070Q(CF) and R1070W(CBAVD) migrated as bands C and B, whereas R1070P(CF) migrated as
bands B and A. The NBF2 mutants D1270N(CBAVD) and G1349D(CF) migrated as band C. “Mock” denotes cells transfected with the GFP
plasmid pTR-UF5. Apparent mass of the proteins, as described in the text, was determined with the RPN800 (Amersham) size markers run in
parallel.
Figure 2 cAMP-stimulated whole-cell chloride currents (ICl2)
recorded from IB3-1 airway cells overexpressing wild-type and mutant
CFTR. The graph presents mean Cl2 currents and standard errors of
the mean (error bars) at 1100 mV (black bars) and -100 mV (gray
bars). Currents at 250 ms are shown for all recordings. The number
of cells patched is indicated in parentheses. For each classification, the
difference between the current magnitude displayed at positive and
negative voltages is attributed to ORCC function; an asterisk indicates
Cl2 currents at positive voltages (1100 mV) that were significantly
greater than the Cl2 currents at negative voltages (2100 mV) (P !
). A double cross indicates current amplitudes of mutant CFTR.05
that were significantly lower than those of wild-type CFTR ( ).P ! .05
NT = not transfected.
lutions. Currents from cells expressing wild-type or
mutant CFTR were significantly greater in magnitude
than were the currents recorded from either nontrans-
fected cells or cells expressing only GFP ( , un-P ! .05
paired Student’s t test; fig. 2). Each of the missense mu-
tants generated robust Cl2 currents comparable to those
of wild-type CFTR (fig. 2). Moreover, Cl2 currents from
cells expressing wild-type CFTR and missense mutants
were significantly greater at positive than at negative
voltages ( , paired Student’s t test), indicating thatP ! .05
their currents were outwardly rectified (fig. 2). There-
fore, each TMD2 and NBF2 mutant that we studied
generated currents that were similar, in magnitude and
rectification, to those of wild-type CFTR. In contrast,
cells transfected with DF508-CFTR produced signifi-
cantly lower Cl2 currents than did those of cells ex-
pressing either wild-type CFTR or any one of the mis-
sense mutants ( ). Furthermore, the current wasP ! .05
not significantly rectified for DF508-CFTR ( forP 1 .05
ICl2 at 1100 mV vs. 2100 mV; fig. 2).
Specific Cl2 channel inhibitors were used to establish
whether the observed whole-cell Cl2 currents were due
to activation of CFTR channels, other ion channels, or
both. Stimulated cells expressing wild-type CFTR dis-
play an outwardly rectifying profile (fig. 3A, blackened
circles). The stilbene derivative DIDS inhibits Cl2 chan-
nels such as ORCCs and anion exchangers but does
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Figure 3 Current-voltage plots of whole-cell patch-clamp data from airway cells transfected with wild-type CFTR and disease-associated
mutants. Mean whole-cell Cl2 currents at 250 ms, as well as standard errors of the mean (error bars), were calculated for each voltage step.
These means were plotted against the voltage steps, to produce the I-V plots. A, cAMP-stimulated IB3-1 cells overexpressing wild-type CFTR,
which generated outwardly rectifying Cl2 current (blackened circles). DIDS (500 mM) eliminated the rectification, leaving a linear I-V profile
(unblackened circles). Glibenclamide (50 mM) blocked CFTR; the remaining current was similar to that in nontransfected cells (crosses). The
NBF1 mutant DF508 generated a linear conductance that was insensitive to DIDS (overlapping blackened and unblackened circles) but responded
to glibenclamide (crosses). B, CBAVD(R1070W)- and CF(R1070P and R1070Q)–associated mutants in TMD2 had I-V plots similar to those
of wild-type CFTR: outwardly rectified currents (blackened circles) that responded to DIDS (unblackened circles) and glibenclamide (crosses).
C, CBAVD(D1270N) and CF(G1349D) mutations in NBF2 had I-V profiles comparable to those of wild-type CFTR.
not inhibit CFTR Cl2 channel activity (Tilmann et al.
1991; Egan et al. 1992; Gabriel et al. 1993; Schwiebert
et al. 1994; Mastrocola et al. 1998; Lee et al. 1999).
The extracellular addition of DIDS to cells expressing
wild-type CFTR eliminated the outwardly rectified
component of the Cl2 currents. The remaining current
had a linear I-V relationship (fig. 3A, unblackened cir-
cles). Glibenclamide inhibits CFTR Cl2 currents (Shep-
pard and Welsh 1993; Schwiebert et al. 1994, 1995;
Fulmer et al. 1995). Application of glibenclamide sig-
nificantly reduced the linear DIDS-insensitive Cl2 cur-
rents, indicating that the current was due to CFTR Cl2
channel activity (fig. 3A, crosses). The residual DIDS-
and glibenclamide-insensitive conductance (1100 mV,
pA; -100 mV, pA;140.5 5 130.0 2214.8 5 97.5 n =
) is similar to that observed for nontransfected cells3
and likely represents current from other endogenous
Cl2 channels. Thus, the combination of I-V relationship
and response to inhibitors allowed dissection of whole-
cell Cl- currents into two components: outwardly rec-
tified and DIDS sensitive, carried by separate channels
such as ORCCs; and linear, DIDS insensitive, and gli-
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Table 2





Band A Band B Band C Cl2 Channel Regulatoryc
Not applicable:
Wild type Normal 2 2 111 111 1
NBF1:d
A455Ee CFe 1 11 2 111 1
DF508 CF 1 11 2 1 2
G551D CF 2 2 111 1 2
TMD2:
R1070W CBAVD 2 1 11 111 1
R1070P CF 1 11 2 111 1
R1070Q CF 2 1 11 111 1
NBF2:
D1270N CBAVD 2 2 111 111 1
G1349D CF 2 2 111 111 1
a A minus sign (2) denotes absence; a single plus sign (1) denotes “low”; a double plus sign
(11) denotes “intermediate”; and a triple plus sign denotes “high.”
b Band designations are as in figure 1.
c Data are for regulation of DIDS-sensitive chloride channels (e.g., ORCCs).
d Data for A455E and G551D have been reported elsewhere (Fulmer et al. 1995).
e Associated with mild lung disease (Gan et al. 1995).
benclamide responsive, generated by CFTR Cl2 chan-
nels.
In contrast to those of wild-type CFTR, the currents
generated from cells expressing the CF-associated mu-
tant DF508 were neither outwardly rectifying nor DIDS
sensitive (fig. 3A, overlap of blackened and unblackened
circles) but were reduced by glibenclamide (fig. 3A,
crosses). Thus, DF508-CFTR functioned as a Cl2 chan-
nel but lacked regulatory function. For each missense
mutant that we studied, the application of DIDS elim-
inated 30%–40% of the whole-cell Cl2 current at 1100
mV ( , paired Student’s t test). Both the CBAVDP ! .05
mutant (R1070W) and the CF mutants (R1070P and
R1070Q) in TMD2 generated outwardly rectified Cl2
currents that were inhibited by DIDS (fig. 3B). In fact,
the I-V and inhibition profiles of all three R1070 mutants
were similar to those of wild-type CFTR (fig. 3B). Like-
wise, cells expressing either of the NBF2 mutants—
D1270N (CBAVD) and G1349D (CF)—had both com-
ponents of whole-cell Cl2 currents (fig. 3C). Glibenclam-
ide reduced currents of each mutant to the same degree
as was observed in cells transfected with wild-type
CFTR. Thus, transient expression of the TMD2 and the
NBF2 mutants restored both CFTR Cl2 channel and
regulatory activities, regardless of the associated pheno-
types.
Discussion
In this article, we have addressed the question of whether
loss of CFTR regulatory function coincides with the pul-
monary phenotype. To test this hypothesis, we evaluated
the effect that CF- and CBAVD-associated mutations
have on both CFTR processing and whole-cell function
(table 2). Our results indicate that processing abnor-
malities do not correlate directly with functional defects.
We were unable to detect mature glycosylated forms for
two mutants, DF508 and R1070P; yet, each of these
generated Cl2 currents attributed to CFTR activity. The
latter observation indicates that a certain amount of
functional CFTR was present in the plasma membrane,
despite the absence of detectable mature protein. One
possibility that may account for this observation is that
CFTR is handled differently in the cells used for func-
tional analyses (IB3-1 cells) than in the cells used to
evaluate processing (HEK 293 cells). Although both cell
lines are models for human epithelial-cell studies, CFTR
in IB3-1 cells is not expressed at levels high enough to
be reliably detected by immunoprecipitation. Thus,
CFTR processing was evaluated in HEK 293 cells. Our
results are comparable to those published by others who
used HEK 293 cells (Seibert et al. 1996). In addition,
other investigators have consistently observed that tran-
siently overexpressed DF508-CFTR retains partial Cl2
channel activity in a variety of cell types (Dalemans et
al. 1991; Drumm et al. 1991; Denning et al. 1992; Cheng
et al. 1995; Frizzell 1995). Thus, incompletely glyco-
sylated “immature” forms of CFTR may be functional,
and, when overexpressed, they may reach the cell
membrane. Alternatively, fully processed forms of CFTR
may have been present but below the limit of detection
by immunoprecipitation.
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To probe the interaction between CFTR and separate
channels, it was necessary to study CFTR in an intact
cell system. The airway cell line IB3-1, which is devoid
of functional CFTR, was selected because complemen-
tation with the wild-type protein restores both CFTR
Cl2 channel activity and CFTR-mediated regulation of
ORCCs (Egan et al. 1992). However, transient over-
expression of the heterologous protein may have con-
cealed the effect that a mutation has on either processing
or function. One could argue that this situation oc-
curred in our analysis of the CFTR regulatory function:
certain mutations affected CFTR regulation, but, when
overexpressed, they appeared to have normal regulatory
function. Although this possibility cannot be excluded,
CFTR regulation of ORCCs is evident over a very wide
range of CFTR expression levels (Ward et al. 1991).
Moreover, an intermediate level of CFTR regulatory
function was not observed for any mutant; regulation
of ORCCs was either present or absent. Thus, the CFTR
regulatory function may be an all-or-none phenomenon
that is independent of CFTR expression level.
Our study of disease-associated mutations suggests
that CFTR regulatory function is mediated by a specific
region. For example, CF-associated mutations in the
NBF1 domain, DF508 (present study), and G551D (Ful-
mer et al. 1995), ablated CFTR regulation of ORCCs,
whereas the regulatory ability was not impaired by mu-
tations in TMD2 and NBF2 (table 2). Of particular note
are the results obtained with the NBF2 mutation
G1349D. The latter mutation is comparable, in terms
of nature (glycine to aspartic acid) and location (Walker
C motif), to the NBF1 mutation G551D; yet, CFTR
bearing G1349D-generated DIDS-sensitive currents
that were attributed to the regulation of ORCCs. These
findings are consistent with functional analyses of syn-
thetic CFTR truncations that indicate that the region
encompassing NBF1 and the R domain is necessary for
CFTR to regulate ORCCs (Schwiebert et al. 1998). Fur-
thermore, the same region appears to mediate CFTR
regulation of ENaC (Schreiberet al. 1999). Yeast two-
hybrid analysis suggests a direct interaction between
NBF1 and the a subunit of ENaC, and also DF508-
CFTR is unable to regulate ENaC (Mall et al. 1996;
Kunzelmann et al. 1997). Likewise, NBF1 appears to
be necessary for the CFTR-ROMK2 interaction that
confers sulfonylurea sensitivity (McNicholas et al.
1997). Together, these observations indicate that NBF1
is critical for CFTR regulation of separate channels.
The importance of the regulatory function in the de-
velopment of the CF phenotype is unknown. Although
synthetic constructs demonstrate that CFTR Cl2 chan-
nel and ORCC regulation were separately mutable, dis-
ease-associated mutations that abolish the regulatory
function without altering the Cl2 channel activity have
not been reported. This may be due to ascertainment
bias: mutations that affect only the regulatory function
might produce a phenotype different from either CF or
CBAVD. Alternatively, CFTR regulation of separate
channels may contribute to the coordination of ion
movement across epithelia in the healthy state, but this
function may become inconsequential when CFTR Cl2
channel activity is altered. Finally, phenotypic impli-
cations of the regulatory function may occur for only
a subset of CFTR mutations, specifically those which
affect the region responsible for regulation. This could
explain the correlation of pulmonary phenotype with
ORCC regulation for mutations in NBF1 and the lack
of correlation for mutations in other regions.
Acknowledgments
The authors thank Drs. Tom Hargrove, Antony Shrimpton,
and Thilo Doerk for clinical and mutation data. We are grate-
ful to Dr. Bill Guggino for critical review of the manuscript.
This work was supported in part by IGA MZ CR grants 2899-
5 and 3526-3 (to M.M.) and by National Institutes of Health
grant DK44003 and Specialized Center for Organized Re-
search grant DK48977 (to G.R.C.).
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
Cystic Fibrosis Genetic Analysis Consortium, http://www
.genet.sickkids.on.ca/CFTR (for R1070W)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nim.nih.gov/Omim (for CF [MIM 219700], CFTR
[MIM 602421], and CBAVD [MIM 277180])
References
Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ
(1991) Generation of cAMP-activated chloride currents by
expression of CFTR. Science 251:679–682
Anderson MP, Welsh MJ (1992) Regulation by ATP and ADP
of CFTR chloride channels that contain mutant nucleotide-
binding domains. Science 257:1701–1704
Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart
C, Maher TA, et al (1992) Congenital bilateral absence of
the vas deferens: a primarily genital form of cystic fibrosis.
JAMA 267:1794–1797
Audre´zet MP, Novelli G, Mercier B, Sangiuolo F, Maceratesi
P, Ferec C, Dallapiccola B (1993) Identification of three
novel cystic fibrosis mutations in a sample of Italian cystic
fibrosis patients. Hum Hered 43:295–300
Bear CE, Li C, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh
M, Riordan JR (1992) Purification and functional reconsti-
tution of the cystic fibrosis transmembrane conductance reg-
ulator (CFTR). Cell 68:809–818
Beaudet AL, Feldman GL, Kobayashi K, Lemna WK, Fernbach
SD, Knowles MR, Boucher RC, et al (1991) Mutation anal-
ysis for cystic fibrosis in a North American population. In:
Mickle et al.: CFTR: Mutations, Functions, and Phenotypes 1493
Tsui LC (ed) The identification of the CF (cystic fibrosis)
gene. Plenum Press, New York, pp 53–54
Bienvenu T, Adjiman M, Thiounn N, Jeanpierre M, Hubert
D, Lepercoq J, Francoual C, et al (1997) Molecular diag-
nosis of congenital bilateral absence of the vas deferens:
analyses of the CFTR gene in 64 French patients. Ann Genet
40:5–9
Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gile LS,
Luisetti M, Pignatti PF (1998) Complete mutational screen-
ing of the CFTR gene in 120 patients with pulmonary dis-
ease. Hum Genet 103:718–722
Casals T, Bassas L, Ruiz-Romero J, Chillon M, Gimenez J,
Ramos MD, Tapia G, et al (1995) Extensive analysis of 40
infertile patients with congenital absence of the vas deferens:
in 50% of cases only one CFTR allele could be detected.
Hum Genet 95:205–211
Cheng SH, Fang SL, Zabner J, Marshall J, Piraino S, Schiavi
SC, Jefferson DM, et al (1995) Functional activation of the
cystic fibrosis trafficking mutant delta F508-CFTR by over
expression. Am J Physiol 268:L615–L624
Cheng SH, Gregory RJ, Marshall J, Paul S, Souzo DW, White
GA, O’Riordan CR, et al (1990) Defective intracellular
transport and processing of CFTR is the molecular basis of
most cystic fibrosis. Cell 63:827–834
Chillo´n M, Casals T, Mercier B, Bassas L, Lissens W, Silber S,
Romey MC, et al (1995) Mutations in the cystic fibrosis
gene in patients with congenital absence of the vas deferens.
N Engl J Med 332:1475–1480
Claustres M, Maguelone L, Desgeorges M, Giansily M, Culard
JF, Razakatsara G, Gerrard B, et al (1993) Analysis of the
27 exons and flanking regions of the cystic fibrosis gene: 40
different mutations account for 91.2% of the mutant alleles
in southern France. Hum Mol Genet 2:1209–1213
Cotton CU, Stutts MJ, Knowles MJ, Gatzy JT, Boucher RC
(1987) Abnormal apical cell membrane in cystic fibrosis res-
piratory epithelium: an in vitro electrophysiologic analysis.
J Clin Invest 79:80–85
Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer
D, Crystal RG, et al (1991) Altered chloride ion channel
kinetics associated with the delta F508 cystic fibrosis mu-
tation. Nature 354:526–528
de la Taille A, Rigot JM, Mahe P, Vankemmel O, Gervais R,
Dumur V, Lemaitre L, et al (1998) Correlation between gen-
ito-urinary anomalies, semen analysis and CFTR genotype
in patients with congenital bilateral absence of the vas def-
erens. Br J Urol 81:614–619
Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE,
Welsh MJ (1992) Processing of mutant cystic fibrosis trans-
membrane conductance regulator is temperature-sensitive.
Nature 358:761–764
Drumm ML, Pope HA, Cliff WH, Rommens JM, Marvin SA,
Tsui LC, Collins FS, et al (1990) Correction of the cystic
fibrosis defect in vitro by retrovirus-mediated gene transfer.
Cell 62:1227–1233
Drumm ML, Wilkinson DJ, Smit LS, Worrell RT, Strong TV,
Frizzell RA, Dawson DC, et al (1991) Chloride conductance
expressed by delta F508 and other mutant CFTRs in Xeno-
pus oocytes. Science 254:1797–1799
Egan M, Flotte TR, Afione SA, Solow R, Zeitlin PL, Carter
BJ, Guggino WB (1992) Defective regulation of outwardly
rectifying Cl2 channels by protein kinase A corrected by
insertion of CFTR. Nature 358:581–584
Estivill X, Bancells C, Ramos C (1997) Geographic distribu-
tion and regional origin of 272 cystic fibrosis mutations in
European populations: The Biomed CF Mutation Analysis
Consortium. Hum Mutat 10:135–154
Fanen P, Clain J, Labarthe R, Hulin P, Girodon E, Pagesy P,
Goossens M, et al (1999) Structure-function analysis of a
double-mutant cystic fibrosis transmembrane conductance
regulator protein occurring in disorders related to cystic fi-
brosis. FEBS Lett 452:371–374
Ferec C, Verlingue C, Parent P, Morin JF, Codet JP, Rault G,
Dagorne M, et al (1995) Neonatal screening for cystic fi-
brosis: result of a pilot study using both immunoreactive
trypsinogen and cystic fibrosis gene mutation analyses. Hum
Genet 96:542–548
Frizzell RA (1995) Functions of the cystic fibrosis transmem-
brane conductance regulator protein. Am J Respir Crit Care
Med 151:S54–S58
Frizzell RA, Rechkemmer G, Shoemaker RL (1986) Altered
regulation of airway epithelial cell chloride channels in cystic
fibrosis. Science 233:558–560
Fulmer SB, Schwiebert EM, Morales MM, Guggino WB, Cut-
ting GR (1995) Two cystic fibrosis transmembrane conduc-
tance regulator mutations have different effects on both pul-
monary phenotype and regulation of outwardly rectified
chloride currents. Proc Natl Acad Sci USA 92:6832–6836
Gabriel SE, Clarke LL, Boucher RC, Stutts MJ (1993) CFTR
and outward rectifying chloride channels are distinct pro-
teins with a regulatory relationship. Nature 363:263–266
Gan K, Veeze HJ, van den Ouweland AMW, Halley DJJ, Schef-
fer H, Van Der Hout A, Overbeek SE, et al (1995) A cystic
fibrosis mutation associated with mild lung disease. N Engl
J Med 333:95–99
Gervais R, Dumur V, Letombe B, Larde A, Rigot JM, Roussel
P, Lafitte JJ (1996) Hypofertility with thick cervical mucus:
another mild form of cystic fibrosis? JAMA 276:1638
Gregory RJ, Cheng SH, Rich DP, Marshall J, Paul S, Hehir K,
Ostegaard L, et al (1990) Expression and characterization
of the cystic fibrosis transmembrane conductance regulator.
Nature 347:382–386
Gregory RJ, Rich DP, Cheng SH, Souza DW, Paul S, Mana-
valan P, Anderson MP, et al (1991) Maturation and function
of cystic fibrosis transmembrane conductance regulator var-
iants bearing mutations in putative nucleotide-binding do-
mains 1 and 2. Mol Cell Biol 11:3886–3893
Grubb BR, Vick RN, Boucher RC (1994) Hyperabsorption of
Na1 and raised Ca21-mediated Cl2 secretion in nasal epi-
thelia of CF mice. Am J Physiol 266:C1478–C1483
Hamosh A, King TM, Rosenstein BJ, Corey M, Levison H,
Durie P, Tsui LC, et al (1992) Cystic fibrosis patients bearing
the common missense mutation GlyrAsp at codon 551 and
the delta F508 are indistinguishable from deltaF508 ho-
mozygotes except for decreased risk of meconium ileus. Am
J Hum Genet 51:245–250
Hwang TC, Lu L, Zeitlin PL, Greunert DC, Huganir RL, Gug-
gino WB (1989) Cl2 channels in CF: lack of activation by
protein kinase C and cAMP-dependent protein kinase. Sci-
ence 244:1351–1353
Ismailov II, Awayda MS, Jovov B, Berdiev BK, Fuller CM,
1494 Am. J. Hum. Genet. 66:1485–1495, 2000
Dedman JR, Daetzel M, et al (1996) Regulation of epithelial
sodium channels by the cystic fibrosis transmembrane con-
ductance regulator. J Biol Chem 271:4725–4732
Jezequel P, Dorval I, Fergelot P, Chauvel B, Le Treut A, Le
Gall JY, Le Lannou D, et al (1995) Structural analysis of
CFTR gene in congenital bilateral absence of vas deferens.
Clin Chem 41:833–835
Johnson LG, Boyles SE, Wilson J, Boucher RC (1995) Nor-
malization of raised sodium absorption and raised calcium-
mediated chloride secretion by adenovirus-mediated ex-
pression of cystic fibrosis transmembrane conductance
regulator in primary human cystic fibrosis airway epithelial
cells. J Clin Invest 95:1377–1382
Jovov B, Ismailov II, Berdiev BK, Fuller CM, Sorscher EJ,
Dedman JR, Kaetzel MA, et al (1995) Interaction between
cystic fibrosis transmembrane conductance regulator and
outwardly rectified chloride channels. J Biol Chem 270:
29194–29200
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox
TK, Chakravarti A, Buchwald M, et al (1989) Identification
of the cystic fibrosis gene: genetic analysis. Science 245:
1073–1080
Kunzelmann K, Kiser GL, Schreiber R, Riordan JR (1997)
Inhibition of epithelial Na1 currents by intracellular do-
mains of the cystic fibrosis transmembrane conductance reg-
ulator. FEBS Lett 400:341–344
Lee MG, Wigley WC, Zeng W, Noel LE, Marino CR, Thomas
PJ, Muallem S (1999) Regulation of Cl2/HCO3
2 exchange
by cystic fibrosis transmembrane conductance regulator ex-
pressed in NIH 3T3 and HEK 293 cells. J Biol Chem 274:
3414–3421
Le Lannou DS, Jezequel P, Blayau M, Dorval I, Lemoine P,
Dabadie A, Roussey M, et al (1995) Obstructive azoosper-
mia with agenesis of vas deferens or with bronchiectasia
(Young’s syndrome): a genetic approach. Hum Reprod 10:
338–341
Li M, McCann JD, Liedtke CM, Nairn AC, Greengard P, Welsh
MJ (1988) Cyclic AMP–dependent protein kinase opens
chloride channels in normal but not cystic fibrosis airway
epithelium. Nature 331:358–360
Mall M, Bleich M, Greger R, Schreiber R, Kunzelmann K
(1998) The amiloride-inhibitable Na1 conductance is re-
duced by the cystic fibrosis transmembrane conductance reg-
ulator in normal but not in cystic fibrosis airways. J Clin
Invest 102:15–21
Mall M, Hipper A, Greger R, Kunzelmann K (1996) Wild type
but not delta F508 CFTR inhibits Na1 conductance when
coexpressed in Xenopus oocytes. FEBS Lett 381:47–52
Mastrocola T, Porcelli AM, Rugolo M (1998) Role of CFTR
and anion exchanger in bicarbonate fluxes in C127 cell lines.
FEBS Lett 440:268–272
McNicholas CM, Nason MW Jr, Guggino WB, Schwiebert
EM, Herbert SC, Giebisch G, Egan ME (1997) A functional
CFTR-NBF1 is required for ROMK2-CFTR interaction. Am
J Physiol 273:F843–F848
Mercier B, Lissens W, Novelli G, Dijeva L, De Arce M, Ka-
pranov N, Canki Klain N, et al (1994) A cluster of cystic
fibrosis mutations in exon 17b of the CFTR gene: a site for
rare mutations. J Med Genet 31:731–734
Mercier B, Lissens W, Novelli G, Kalydjieva L, De Arce M,
Kapranov N, Klain NC, et al (1993) Identification of eight
novel mutations in a collaborative analysis of a part of the
second transmembrane domain of the CFTR gene. Genomics
16:296–297
Mercier B, Verlingue C, Lissens W, Silber SJ, Novelli G, Bon-
duelle M, Audrezet MP, et al (1995) Is congenital bilateral
absence of vas deferens a primary form of cystic fibrosis?
analyses of the CFTR gene in 67 patients. Am J Med Genet
56:272–277
Mickle J, Macek M Jr, Fulmer-Smentek SB, Egan M, Schwie-
bert EM, Guggino W, Moss R, et al (1998) A mutation in
the cystic fibrosis transmembrane conductance regulator
gene associated with elevated sweat chloride concentrations
in the absence of cystic fibrosis. Hum Mol Genet 7:729–735
Osborne LR, Lynch M, Middleton PG, Alton EWFW, Geddes
DM, Pryor JP, Hodson ME, et al (1993) Nasal epithelial ion
transport and genetic analysis of infertile men with congen-
ital bilateral absence of the vas deferens. Hum Mol Genet
2:1605–1609
Reddy MM, Light MJ, Quinton PM (1999) Activation of the
epithelial Na1 channel (ENaC) requires CFTR Cl2 channel
function. Nature 402:301–304
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R,
Grzelczak Z, Zielenski J, et al (1989) Identification of the
cystic fibrosis gene: cloning and characterization of com-
plementary DNA. Science 245:1066–1073
Savov A, Mercier B, Kalaydjieva L, Fe´rec C (1994) Identifi-
cation of six novel mutations in the CFTR gene of patients
from Bulgaria by screening the twenty seven exons and exon/
intron boundaries using DGGE and direct DNA sequencing.
Hum Mol Genet 3:57–60
Schreiber R, Hopf A, Mall M, Greger R, Kunzelmann K (1999)
The first-nucleotide binding domain of the cystic fibrosis
transmembrane conductance regulator is important for in-
hibition of the epithelial Na1 channel. Proc Natl Acad Sci
USA 96:5310–5315
Schwiebert EM, Egan ME, Hwang T, Fulmer SB, Allen SS,
Cutting GR, Guggino WB (1995) CFTR regulates outwardly
rectifying chloride channels through an autocrine mecha-
nism involving ATP. Cell 81:1–20
Schwiebert EM, Flotte T, Cutting GR, Guggino WB (1994)
Both CFTR and outwardly rectifying chloride channels con-
tribute to cAMP-stimulated whole cell chloride currents. Am
J Physiol 266:C1464–C1477
Schwiebert EM, Morales MM, Devidas S, Egan ME, Guggino
WB (1998) Chloride channel and chloride conductance reg-
ulator domains of CFTR, the cystic fibrosis transmembrane
conductance regulator. Proc Natl Acad Sci USA 95:2674
–2679
Seibert FS, Linsdell P, Loo TW, Hanrahan JW, Clarke DM,
Riordan JR (1996) Disease-associated mutations in the
fourth cytoplasmic loop of cystic fibrosis transmembrane
conductance regulator compromise biosynthetic processing
and chloride channel activity. J Biol Chem 271:15139–
15145
Sheppard DN, Welsh MJ (1993) Inhibition of the cystic fibrosis
transmembrane conductance regulator by ATP-sensitive po-
tassium channel regulators. Ann NY Acad Sci 707:275–284
Shrimpton AE, Borowitz DC, Swender P (1997) Cystic fibrosis
Mickle et al.: CFTR: Mutations, Functions, and Phenotypes 1495
mutation frequencies in upstate New York. Hum Mutat 10:
436–442
Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA,
Rossier BC, Boucher RC (1995) CFTR as a cAMP-depen-
dent regulator of sodium channels. Science 269:847–850
Tilmann M, Kunzelmann K, Frobe U, Cabantchik I, Lang HJ,
Englert HC, Greger R (1991) Different types of blockers of
the intermediate-conductance outwardly rectifying chloride
channel in epithelia. Pflu¨gers Arch 418:556–563
Verlingue C, David A, Audrezet MP, Le Roux MG, Mercier
B, Moisan JP, Ferec C (1993) Asymptomatic carrier of two
CFTR mutations: consequences for prenatal diagnosis?
Prenat Diagn 13:1143–1148
Ward CL, Krouse ME, Gruenert DC, Kopito RR, Wine JJ
(1991) Cystic fibrosis gene expression is not correlated with
rectifying Cl2 channels. Proc Natl Acad Sci USA 88:
5277–5281
Welsh MJ, Liedtke CM (1986) Chloride and potassium chan-
nels in cystic fibrosis airway epithelia. Nature 322:467–470
Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR
chloride channel dysfunction in cystic fibrosis. Cell 73:
1251–1254
Welsh MJ, Tsui L, Boat TF, Beaudet AL (1995) Cystic fibrosis.
In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The met-
abolic and molecular bases of inherited disease. McGraw-
Hill, New York, pp 3799–3876
Youssoufian G, Auerbach AD, Verlander PC, Steimle V, Mach
B (1995) Identification of cytosolic proteins that bind to the
Fanconi anemia complementation group C polypeptide in
vitro. J Biol Chem 270:9876–9882
Zeitlin PL, Lu L, Hwang TC, Rhim J, Craig R, Cutting GR,
Stetton G, et al (1991) A cystic fibrosis bronchial epithelial
cell line: immortalization by Adeno-12-SV40 infection. Am
J Respir Cell Mol Biol 4:313–319
Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N
(1996) A “humanized” green fluorescent protein cDNA
adapted for high-level expression in mammalian cells. J Virol
70:4646–4654
